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Abstract 
Favourable outcomes of peptide receptor radiotherapy (PRRT) of neuroendocrine tumours 
have been reported during the last years. Still, there are uncertainties on the radionuclides to 
be used, the treatment planning, and the indication in patients with a high proliferation rate. 
This case report describes a patient with a high tumour burden of poorly differentiated 
neuroendocrine carcinoma of unknown primary with a proliferation rate in liver metastases 
up to 50%, undergoing fractionated treatment with 7 cycles of 
177Lu-DOTA-octreotate (7.4 
GBq each) after disease progression on two different chemotherapy regiments. Based on 
initial staging scintigraphy, somatostatin receptor expression was very high.  
Longitudinal dosimetry studies during therapy indicated ongoing increases in tumour-to-organ 
ratios that coincided with an objective response.  
We conclude that fractionated therapy with 
177Lu-DOTA-octreotate should be considered a 
treatment option also for those patients with large tumours, high proliferation, and high 
receptor expression. 
Key words: Neuroendocrine tumour, PRRT, 177Lu-DOTA-octreotate, radionuclide therapy, do-
simetry. 
Introduction 
During  the  last  decade,  encouraging  reports 
from  patients  with  neuroendocrine  tumours  under-
going targeted radionuclide therapy with somatosta-
tin  analogues  (often  referred  to  as  peptide  receptor 
radionuclide  therapy,  PRRT)  have  increased.  The 
largest  numbers  of  patients  reported  have  been 
treated  with  90Y-DOTATOC  [1]  and  177Lu-DOTA- 
octreotate [2, 3]. The results document the possibility 
of  obtaining  objective  tumour  responses  in  patients 
failing to respond to traditional biologic and cytotoxic 
chemotherapeutics.  Radionuclide  therapy  targeting 
somatostatin  receptors  is  the  second  of  its  kind  to 
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show objective tumour responses in a larger group of 
patients with solid tumours since the start of radioio-
dine treatment for thyroid carcinoma, only preceded 
by therapy with meta-iodobenzylbiguanidine (MIBG) 
[4-6]. Risk organs are kidneys and the bone marrow. 
Experience from radioiodine therapy [7] and ex-
ternal  beam  radiation  [8]  have  been  the  reference 
points  regarding  therapy  planning  and  dosimetry. 
However,  there  are  important  differences  to  be 
acknowledged. 
Unlike  radioiodine  treatment,  some  patients 
treated with PRRT can have extremely dramatic re-
sults. Also, exposure to significant amounts of 131I has 
been reported to impair uptake in consecutive treat-
ments due to down-regulation of the sodium/iodide 
symporter [9, 10]. On the contrary, up-regulation of 
somatostatin receptors escaping from low-dose irra-
diation has been described in animal models [11].  
PRRT differs from external beam radiation be-
cause of the biological variables that influence radia-
tion exposure. The radiation dose to the tumour as 
well as to normal organs is a function of the availabil-
ity of the tracer, which is dependent on tumour size, 
receptor  density  and  the  amount  and  pharmacoki-
netic  of  the  tracer.  In  other  words,  the  physician 
planning PRRT cannot prescribe an absorbed tumour 
dose, but a certain amount of activity, that eventually 
results in a tumour or organ dose, depending on re-
sults of previous treatments and the patient’s present 
general condition.  
Peptide receptor radionuclide therapy with so-
matostatin  analogues  is  a  new  treatment  modality 
with new inherent rules, which have to be explored. 
177Lu-DOTA-octreotate  is  a  suitable  tracer  both  for 
treatment and imaging, emitting both a major fraction 
of beta particles for therapy, and a smaller fraction of 
gamma  rays  with  good  qualities  for  imaging.  Con-
tinuous imaging and dosimetry of patients undergo-
ing  several  cycles  with  177Lu-DOTA-octreotate  can 
provide important insights on the effects of previous 
cycles of therapy.  
Thus far, about 300 patients with different neu-
roendocrine  tumours  have  been  treated  with 
177Lu-DOTA-octreotate  in  our  institution  in  close  to 
1200 cycles. By performing dosimetry of the kidneys, 
spleen,  liver,  and  tumours  with  a  previously  de-
scribed  method  based  on  3-D  imaging  with  small 
volumes of interest [12], some patients have revealed 
unexpected or unusual uptake and response patterns. 
The method is based on the repetitive measurement of 
the activity concentration in small volumes of 4 ml in 
areas  with  fairly  homogeneous  distributed  uptake. 
Here, we report on the findings in a patient under-
going 7 cycles with 7.4 GBq of 177Lu-DOTA-octreotate 
each.  
Patient description 
A  previously  healthy  42-year-old  woman  pre-
sented with itching and abdominal discomfort in De-
cember 2008. In early 2009, she was diagnosed with 
poorly differentiated neuroendocrine carcinoma with 
disseminated disease in the liver, abdominal, thoracic 
and pelvic lymph nodes. Small bone metastases were 
suspected in the sacrum and the thoracic spine. The 
primary tumour was not found. Liver biopsies at two 
different  time  points  from  several  liver  metastases 
revealed a Ki-67 rate between 10 and 50%. Somato-
statin  receptor  scintigraphy  in  March  2009  showed 
very high uptake in all known tumour lesions (Figure 
1). Initial treatment commenced with cisplatinum and 
etoposide in April 2009. In September 2009, evalua-
tion  showed  tumour  progression  and  therapy  was 
changed  to  a  combination  of  temozolomide  and 
capecitabine  until  response  evaluation  in  February 
2010 showed further disease progression. The tumour 
burden in the liver had grown abundant by this time, 
engaging  more  than  50%  of  the  total  volume  with 
decreasing liver function (Figure 2) and chemothera-
py  was  stopped.  She  was  not  a  candidate  for  liver 
directed therapy. Since somatostatin receptor scintig-
raphy before start of chemotherapy had shown a very 
high expression of somatostatin receptors (grade 4), 
she  was  considered  for  treatment  with 
177Lu-DOTA-octreotate.  By  then,  the  glomerular  fil-
tration  rate  had  decreased  from  already  subnormal 
values  (normal  range,  age  adjusted  >80 
ml/min/1,73m2) at the time of diagnosis down to 41 
ml/min/1,73m2 before the first cycle (Figure 2). Be-
tween  May  2010  and  August  2011,  the  patient  re-
ceived 7 cycles of 177Lu-DOTA-octreotate with an ac-
tivity  of  7.4  GBq  each,  after  giving  her  written  in-
formed  consent.  During  chemotherapy,  the  patient 
developed a pulmonary embolism and started treat-
ment with fraxiparine. In September 2010, following 
the second cycle of 177Lu-DOTA-octreotate, she had a 
sudden drop in platelets, as part of a paramalignant 
phenomenon.  She  recovered  after  several  weeks  of 
prednisolone  and  fraxiparine;  later  cycles  of  PRRT 
were administered without any delay (Figure 3). In 
November 2011, the patient is in good general health 
without any tumour related symptoms. 
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Figure 1. Somatostatin receptor scintigraphy (111In-DTPA-octreotide, OctreoScan®) in March 2009; Whole body scan, anterior and 
posterior view. 
 
 
 
Figure 2. Glomerular filtration rate (GFR) according to the Cystatin C method, S-albumin and S-creatinine as a function of treatment.  
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Figure 3. Blood cell counts during therapy with 177Lu-DOTA-octreotate. 
 
 
Methods 
Therapy protocol 
The  DOTA-octreotate  (Mallinckrodt,  St  Louis, 
MO) was a generous gift of Prof. Eric Krenning, Rot-
terdam, distributed by NRG, Petten, The Netherlands. 
177LuCl3 was obtained from IDB, Petten, The Nether-
lands. Kidney protection was given with a commer-
cially available mixed amino acid solution (Vamin 14g 
N/l  electrolyte  free,  Fresenius  Kabi,  Sweden  ®),  2 
Litres at an infusion speed of 250mL/min were ad-
ministered intravenously along with the first 5 cycles, 
4 Litres with the last two, commencing 30 min before 
the  radionuclide  infusion.  Seven  cycles  were  given, 
aiming at an interval of 6 to 8 weeks. 
Dosimetry 
Full  dosimetry  as  described  earlier  [12]  was 
performed during cycles 1, 3 and 6, based on SPECT 
with low-dose CT for attenuation correction at 24 hrs, 
4 and 7 days after therapy, whole body scan directly 
after  the  treatment  and  at  the  same  time  points  as 
SPECT-CT as well as blood samples taken at 6 time 
points during the first 24hrs after treatment for cal-
culation  of  a  blood  activity  curve.  Within  kidneys, 
liver  spleen  and  representative  tumours,  small  vol-
umes of interests (VOI) of 4 ml were drawn in areas 
with  homogeneous  activity  distribution.  During  all 
other  cycles,  the  uptake  intensity  in  tumours  and 
kidneys was calculated based on 24 hrs post therapy 
imaging  with  SPECT-CT  and  whole  body  scan,  as-
suming the same effective half-life as calculated from 
the previous complete dosimetry [13]. For dosimetry 
during cycle 1, the reported tumour VOI was drawn 
in  areas  representing  the  highest  uptake  within  the 
respective metastasis. For the subsequent calculations 
the same areas within the tumours were identified.  
Imaging was performed on an Infinia (Interna-
tional  General  Electric,  General  Electric  Health  Sys-
tems,  Haifa,  Israel)  dual  headed  camera  with  3/8“ 
thick NaI (Tl)-crystals with VPC-5 (MEGP) collima-
tors. Bone marrow dosimetry was based on a) calcu-
lation of the self-dose derived from the blood and b) 
calculation of the dose contribution from the rest of 
the  body,  including  tumour,  based  on  whole  body 
scans.  The  detailed  description  of  the  calculation  is 
subject of a forthcoming report.  
Response  control  was  performed  on  contrast 
enhanced  CT  according  to  RECIST  1.1  [14]  criteria 
after cycle 2, 4 and three months after cycle 7. Theranostics 2012, 2(5) 
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Results 
Tumour response 
Figure 4 demonstrates the growth of the largest 
metastasis  in  the  liver  representing  the  main  total 
tumour  burden,  measured  according  to  RECIST  in 
contrast  enhanced  CT  images.  Combined  chemo-
therapy managed to decrease only slightly the diam-
eter  of  a  pelvic  tumour,  while  all  other  metastases 
continued  to  grow  in  size.  After  the  initiation  of 
PRRT,  all  metastases  decreased  on  treatment  with 
177Lu-DOTA-octreotate  and  continued  to  do  so  at 
subsequent  times  of  evaluation.  Three  months  after 
cycle 7, all liver metastases showed radiological signs 
of  necrosis.  The  sum  of  the  tumour  diameters  de-
creased by 44% according to RECIST since the start of 
PRRT, corresponding to a partial remission. Also ac-
cording to the scintigraphy acquired during each cy-
cle,  the  total  tumour  burden  continued  to  decrease 
throughout the whole therapy (Figure 5, whole body 
scans at 24 hrs after infusion, cycle 1 to 7; upper row 
anterior views, lower row posterior views). Figure 6 
illustrates  the  volume  reduction  of  the  liver  along 
with the tumour burden on sagittal views at start of 
PRRT and during the final treatment cycle. The right 
kidney, dislocated at start of PRRT, had returned back 
to its normal anatomical place by cycle 7 (arrow).  
 
Figure 4. Diameters of the largest tumours, evaluated according to RECIST 1.1 criteria 
 
Figure 5. Whole Body Scan 24 hrs after treatment. Upper row anterior view, lower row corresponding posterior view. Theranostics 2012, 2(5) 
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Figure  6.  Sagittal  views  of  SPECT-CT  over  the  abdomen  at  the  level  of  the  right  kidney,  24  hrs  after  infusion  of  7.4  GBq  of 
177Lu-DOTA-octreotate. a) Cycle 1, May 2010 b) cycle 7, August 2011. Left upper corner in each image: attenuation correction CT, right 
upper corner attenuation corrected SPECT, left lower corner fused SPECT-CT, right lower corner maximum intensity projection (MIP). 
Note the position of the right kidney (arrow) and tracer distribution within the tumours. 
 
 
 
Dosimetry of kidneys and bone marrow 
After  seven  cycles  of  177Lu-DOTA-octreotate 
with 7.4 GBq each, dosimetry according to the previ-
ously described small VOI method [12] [13] indicated 
an accumulated absorbed dose to the right kidney of 
25.4 Gy and 24.4 Gy to the left kidney. The absorbed 
doses to the kidneys remained essentially on the same 
level during the first 4 cycles, but increased towards 
the end of the treatment (Figure 7). The dose to the 
spleen decreased slightly. The absorbed dose do the 
bone  marrow  decreased  throughout  the  treatment, 
both the self-dose calculated from the blood activity 
(89, 75, 60 mGy at cycle 1, 3 and 6), as well as the 
photon contribution from solid organs, tumours and 
the remainder of the body (121, 106, 78 mGy, respec-
tively). 
Tumour dosimetry 
Applying  the  same  method  as  previously  de-
scribed  for  solid  organs  to  the  tumours  [12],  all 
measured tumours increased their activity concentra-
tion  and,  as  a  consequence,  the  absorbed  dose 
throughout the course of therapy. Figure 7, 8 and 9 
show the calculated doses for the largest metastases in 
the liver, one in each lobe, at cycle 1, 3 and 6. The areas 
that  were  chosen  represented  the  highest  uptake  at 
cycle 1. The activity distribution grows more homo-
geneous during the treatment, while the tumour ap-
pears to shrink concentrically according to the fused 
SPECT-CT  images.  This  implies  an  even  more  pro-
nounced increase of uptake in tumour areas outside 
those areas that are shown here. The more homoge-
neous  activity  distribution  in  the  remainder  of  the 
large liver metastases is obvious in Figure 6. 
Kidney function 
Figure  1  illustrates  the  development  of  kidney 
function expressed by creatinine and the glomerular 
filtration  rate  (GFR)  according  to  the  cystatin  C 
method. Meanwhile creatinine levels throughout the 
whole treatment were within normal ranges; the GFR 
decreased further during chemotherapy from already 
abnormal  values.  After  the  start  of 
177Lu-DOTA-octreotate,  the  GFR  consecutively  in-
creased to a normal level (> 80ml/min/1.73 m2) by the 
time of the last cycle and remained there at the time of 
first post-treatment evaluation. 
Bone Marrow Function 
During the initial phase of therapy, the patient 
suffered  from  repetitive  lung  embolism  and,  after 
cycle 2 of 177Lu-DOTA-octreotate, of a sudden drop of 
platelets.  This  was  assessed  to  represent  a  parama-Theranostics 2012, 2(5) 
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lignant phenomenon, rather than radiation induced. 
After  treatment  with  prednisolone  and  fraxiparine, 
the patient recovered to good health, and platelets as 
well as total white blood cell counts and hemoglobine 
remained within normal ranges throughout the fur-
ther treatment (Figure 3). 
 
 
 
 
 
Figure 7. Absorbed doses to kidneys, liver parenchyma, spleen and the two largest liver metastases, one for each lobe. Data from 
complete dosimetry at cycle 1 (May 2010) cycle 3 (October 2010) and cycle 6 (April 2011). Absorbed doses are calculated from 
SPECT-CT data according to the previously published method, using small volumes of interest (VOI) [12]. Note the increase of tumour 
doses during therapy. At first cycle, the area of measurement was placed in the hot spot of either metastasis; in latter cycles, corre-
sponding areas were identified and evaluated. Bone marrow dosimetry: Self-dose calculated from blood-activity curve, total absorbed 
dose in the bone marrow calculated from cross-fire dose and self-dose. 
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Figure 8. SPECT-CT images (left) and corresponding diagnostic CT (right) of largest liver metastasis in the right liver lobe at time of 
dosimetry at cycle 1, 3 and 6 (top to bottom). SPECT-CT images: left upper corner attenuation correction CT, right upper corner 
attenuation corrected SPECT, left lower corner fused SPECT-CT (all transversal views), right lower corner maximum intensity projection 
(MIP). Note the concentric shrinkage of the tumour and the increasing homogeneity of the uptake distribution. 
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Figure 9. SPECT-CT images (left) and corresponding diagnostic CT (right) of largest liver metastasis in the left liver lobe at time of 
dosimetry at cycle 1, 3 and 6 (top to bottom). SPECT-CT images: left upper corner attenuation correction CT, right upper corner 
attenuation corrected SPECT, left lower corner fused SPECT-CT (all transversal views), right lower corner maximum intensity projection 
(MIP). Note the concentric shrinkage of the tumour and the increasing homogeneity of the uptake distribution. 
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Discussion 
There are several lessons to be learned from this 
patient’s history. 
1) Increasing receptor uptake during therapy 
is not always an ominous sign 
Amount of tracer in relation to the total amount of re-
ceptors 
Molecular imaging, especially with  18FDG-PET, 
has  taught  us  that  decrease  of  uptake  is  mirroring 
decrease of tumour activity. Previous observations of 
patients  undergoing  PRRT  with 
177Lu-DOTA-octreotate  have  shown  a  correlation  of 
decrease in uptake and patient outcome [2]. In this 
patient’s example, a very high pre-treatment uptake 
was combined with a large tumour burden. The in-
crease of uptake, and as a result, the absorbed dose to 
the tumours occurred simultaneously with an objec-
tive decrease of tumour burden assessed by RECIST 
criteria, in agreement with findings on scintigraphy. 
This suggests, that at least in part, the increase of up-
take is due to an increased availability of tracer as a 
result of a decrease of the total number of receptors.  
In a patient with an amount of tumour receptors 
vastly exceeding the amount of available tracer, this 
phenomenon  might  occur  until  the  tumour  volume 
has decreased and the total amount of tumour recep-
tors is lower than the amount of available tracer.  
Tumour response may also be accompanied with 
an increased absorption of necrotic tumour cells act-
ing as “spacers” between cells with receptor uptake, 
which in turn can improve absorbed doses through an 
increase of cross-fire. 
Receptor up-regulation 
There are additional and contributory explana-
tions. Receptor up-regulation in tumour cells surviv-
ing  low  dose  radiation  is  one  possible  explanation, 
and has been discussed based on results in a rodent 
model[11].  Without  the  ability  to  quantify  the  total 
amount of receptors before and after treatment, this 
concept remains hard to prove in patient treatment. 
Quantitative PET imaging may help to solve this. This 
approach must take into account the possibility, that 
the total amount of receptors in a patient might not be 
saturated by a tracer dose. This has a direct impact, if 
the results of PET imaging are going to be used for 
future therapy planning for PRRT.  
Accumulation of tracer throughout the therapy 
Another contributing factor of increased tumour 
uptake during PRRT is the possible accumulation of 
the radionuclide after previous cycles of treatments, 
especially  in  tumours  with  high  tumour  uptake.  In 
other patients, we have been able to detect activity in 
tumour as long as several months after a treatment 
cycle.  
2) Potential nephrotoxicity must be seen in the 
light of the tumour burden 
Confounders in the assessment of kidney function 
The described patient showed before the start of 
PRRT a steady increase of tumour burden along with 
decrease of glomerular filtration rate, calculated from 
cystatin  C.  Nevertheless,  creatinine  remained  basi-
cally unchanged throughout the whole treatment, and 
urea decreased from levels in the upper normal range 
to the lower, with highest values during chemother-
apy (data not shown). Cystatin C has been reported to 
be a valuable marker of kidney function for patients 
undergoing  chemotherapy  [15].  However,  Kos  et  al 
reports on increased Cystatin C levels in patients with 
colorectal cancers and malignant melanoma [16] as a 
possible  source  of  underestimation  of  the  kidney 
function in patients with these types of malignancy.  
The findings in this patient may indicate, that the 
tumour secrets Cystatin C leading to an underestima-
tion of the kidney function, given the fact that urea 
and creatinine remained within the normal range. It is 
interesting though, that an improvement of the cal-
culated GFR occurred during PRRT, a phenomenon 
we  have  encountered  in  several  patients.  Thus,  the 
kidney function in neuroendocrine cancers should not 
be deemed from only one functional test, since false 
low  results  can  prevent  treatment  in  patients  with 
potential gain from PRRT.  
Relevance of the choice of tracer and radionuclide for the 
concept of fractionated radionuclide therapy 
Adequate kidney function is an important pre-
requisite for PRRT, and several authors have reported 
on impairment of kidney function after PRRT [1, 17, 
18].  Esser  et  al  compared  the  residence  time  in  tu-
mours, kidneys and spleen for 177Lu-DOTA-octreotate 
and 177Lu-DOTATOC in 7 patients and concluded that 
177Lu-DOTA-octreotate  had  about  1.5  times  longer 
residence time in tumours as compared to the kidneys 
[19].  Increased  residence  time  in  the  tumour  com-
pared  to  the  kidney  is  especially  advantageous  for 
isotopes with a longer half-life. Reubi et al [20] dis-
cussed  the  impact  of  the  introduction  of  different 
chelators and of radiometals on the affinity of a so-
matostatin  analogue,  finding  a  ninefold  increase  in 
affinity for receptor type 2 when comparing [DOTA0, 
Tyr3]  octreotate  and  [DOTA0,  Tyr3]  octreotide. 
Kwekkeboom  et  al  found  three-  to  fourfold  higher 
uptake  in  4  out  of  5  tumours  with  basically  un-Theranostics 2012, 2(5) 
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changed  uptake  in  kidneys  and  spleen,  when  com-
paring  patients  treated  with  [177Lu-DOTA0Tyr3]  oc-
treotate  and  [111In-DTPA0]  octreotide  [21].  Optimal 
tumour-over-kidney uptake is crucial for an optimal 
treatment result. Taking into account the shorter tis-
sue penetration range of 177Lu as compared to 90Y, the 
same  group  draws  the  conclusion  that 
177Lu-DOTA-octreotate is the radiolabeled somatosta-
tin analogue of choice for PRRT [22].  
This patient’s example supports in our opinion 
this view and adds another aspect.  
This is to our knowledge the first time that an 
increase  of  tumour-to-kidney  and  tumour-to-bone 
marrow  dose  is  reported  in  a  patient  undergoing 
fractionated  therapy  with  177Lu-DOTA-octreotate. 
This demonstrates the possible advantage of a frac-
tioned  therapy  approach,  with  improved  tu-
mour-to-risk  organ  dose  as  a  result  of  previous 
treatment cycles. The amount of activity administered 
in this patient would not have been possible with a 90Y 
labelled compound, neither the described approach of 
dosimetry.  
Fractionated therapy seems to be especially im-
portant in large lesions with high uptake, when the 
follow-up  scans  indicate  an  improved,  more  homo-
geneous  distribution  pattern.  This  leads  to  the  next 
conclusion to be drawn from this patient’s example. 
3) 177Lu is a suitable radionuclide for the 
treatment of large tumours 
Fractionated therapy as a mean to improve tumour re-
sponse at low toxicity to risk organs: 
177Lu versus 
90Y 
This patient’s example clearly demonstrates the 
potential  of  177Lu-DOTA-octreotate  to  reduce  large 
tumour volumes. Figure 4 shows that 4 out of 5 tu-
mours were at least 10 cm in diameter when PRRT 
with commenced. Previous reports have been stress-
ing the superiority of 90Y over 177Lu for the treatment 
of large tumours, partly based on animal results, and 
partly based on the physical properties of  90Y with a 
higher beta energy and a longer range in tissue com-
pared to 177Lu [23-25]. The recent report from the Basel 
group of a series of 1109 patients undergoing treat-
ment  with  90Y-DOTATOC  described  morphological 
responses in 34.1 %, with a side effect of permanent 
renal toxicity in 9.2 % [1]. The treatment was given 
with a median of 2 cycles per patient. Barone et al [26] 
observed, that kidney toxicity during treatment with 
90Y-DOTATOC  was  increased  in  patients  with  low 
fractionation. Their conclusion was that kidney vol-
umes, dose rate and fractionation play important roles 
for  kidney  dosimetry  and  the  prediction  of  ne-
phrotoxicity.  The  same  group  reported  also  a  dose 
relationship between tumour dose estimates and re-
sponse [27], a finding that compares well to clinical 
experience from external beam radiation 
The observation in our present patient of an im-
proved tumour-to-organ dose ratio as a function of 
previous cycles of therapy adds a new aspect to the 
discussion.  177Lu has in comparison to  90Y a shorter 
range in tissue and offers the advantage of lower ir-
radiation of structures adjacent to the tumours.  Re-
peated cycles of  177Lu-DOTA-octreotate may lead to 
improved tumour dose absorption doses at the cost of 
comparatively  low  kidney  toxicity,  if  scanning  and 
dosimetry under therapy shows an improved, more 
homogeneous uptake pattern in  the tumour. Under 
these circumstances, also the longer half-life of 177Lu is 
an  advantage,  since  the  ratio  of  tumour-to 
non-tumour  irradiation  improves  over  time.  Thus, 
very  high,  and  potentially  tumoricidal  accumulated 
absorbed doses can be achieved (Figure 7). In our ex-
perience, this pattern is especially common in hindgut 
tumours with a large tumour burden (data in prepa-
ration). 
The potential for fractionated PRRT treatment in 
patients with high tumour burden, using surveillance 
dosimetry should be the subject of further evaluation. 
A  recent  report  on  the  comparison  between  PRRT 
with  90Y-DOTATATE  and  90Y/177Lu-DOTATE  indi-
cates a survival advantage for the combination ther-
apy [28]. Our reported findings suggest that a dosim-
etry-based  approach  with  177Lu-DOTA-octreotate 
might be advantageous over 90Y-labeled somatostatin 
analogues  and  possibly  even  combination  therapy, 
and should be regarded as a veritable contestant for a 
randomized study, as suggested by Brans et al. in a 
reply to this article [29].  
The described case highlights still one other as-
pect of the discussion interesting clinicians involved 
in the treatment of patients with neuroendocrine tu-
mours. 
4) High proliferation should not exclude a pa-
tient per se from radionuclide therapy 
Proliferation rate and somatostatin receptor expression 
The ENETS clinical guidelines for the treatment 
of poorly differentiated neuroendocrine tumours with 
high proliferation rate recommend cisplatinum-based 
chemotherapy as first line treatment [30-32], yielding 
an objective response rate of 60 to 70%, with a dura-
tion of 8 to 9 months. High proliferation is generally 
regarded as an indicator of low somatostatin receptor 
expression, and somatostatin scintigraphy is not reg-
ularly performed for this reason [32]. The very high 
uptake in the pre-therapeutic somatostatin scintigra-Theranostics 2012, 2(5) 
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phy  was  in  favour  of  our  patient.  Only  recently,  a 
report  focusing  on  the  results  of  PRRT  with 
177Lu-DOTA-octreotate in 81 patients with respect to 
proliferation rate found comparable outcome in pa-
tients with proliferation rates up to 20%, with partial 
responses in 40%, minor responses in 15% and stable 
disease in another 34%, with 11% in progressive dis-
ease [33]. Only 2 out of 7 patients with a proliferation 
rate  over  20%  responded  to  the  treatment  that  had 
been given in four cycles with a mean activity of 7.9 
GBq at standard intervals of 3 months (10-14 weeks). 
In  accordance  with  previous  reports  [2],  a  positive 
correlation  of  uptake  intensity  and  outcome  was 
found.  
Proliferation rate and treatment plan 
Also in this setting, the patient we report on is a 
unique case, with a high proliferative tumour that has 
responded  favourably  to  PRRT  with 
177Lu-DOTA-octreotate. Tumours with high prolifera-
tion tend to have a quick tumour recovery, and the 
time  elapsed  between  treatment  cycles  is  of  signifi-
cance. In our opinion, if considering PRRT in the case 
of  highly  proliferative  tumours,  treatment  intervals 
should be kept as short as possible, side effects such as 
bone marrow suppression taken into account.  
The example of our patient is a proof of concept 
that  treatment  with  177Lu-DOTA-octreotate  can  be 
effective  for  patients  with  a  proliferation  rate  over 
20%, given a high receptor density. Also in this group 
of  patients,  the  presence  of  somatostatin  receptors 
should be evaluated. 
Conclusion 
The reported patient illustrates that fractionated 
therapy  with  177Lu-DOTA-octreotate  based  on  do-
simetry can improve the tumour-to-tissue dose due to 
increased  tumour  uptake  as  a  result  of  previous 
treatment  cycles.  Tumoricidal  absorbed  radiation 
doses can be achieved despite large tumours and high 
proliferation  rate.  Imaging  and  dosimetry  during 
therapy is a valuable tool for treatment planning and 
for the evaluation of the outcome. 
Acknowledgements 
The authors would like to thank Prof. Eric Kren-
ning for the generous peptide supply. With gratitude 
we acknowledge Assistant Prof. Eric Liu for his lin-
guistic help. We also would like to thank our patient 
for giving her consent to publish the provided images 
and data. 
Competing Interests 
The  authors  have  declared  that  no  competing 
interest exists. 
References 
1.  Imhof A, Brunner P, Marincek N, Briel M, Schindler C, Rasch H, 
Macke HR, Rochlitz C, Muller-Brand J, and Walter MA. Response, 
survival, and long-term toxicity after therapy with the radiolabeled 
somatostatin  analogue  [90Y-DOTA]-TOC  in  metastasized 
neuroendocrine cancers. J Clin Oncol. 2011; 29(17): 2416-23. 
2.  Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, de Herder 
WW, Feelders RA, van Eijck CH, Esser JP, Kam BL, and Krenning 
EP.  Radiolabeled  somatostatin  analog 
[177Lu-DOTA0,Tyr3]octreotate  in  patients  with  endocrine 
gastroenteropancreatic tumors. J Clin Oncol. 2005; 23(12): 2754-62. 
3.  Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen 
M,  Kooij  PP,  Feelders  RA,  van  Aken  MO,  and  Krenning  EP. 
Treatment  with  the  radiolabeled  somatostatin  analog  [177 
Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin 
Oncol. 2008; 26(13): 2124-30. 
4.  Hoefnagel  CA.  Metaiodobenzylguanidine  and  somatostatin  in 
oncology: role in the management of neural crest tumours. Eur J 
Nucl Med. 1994; 21(6): 561-81. 
5.  Hoefnagel  CA,  De  Kraker  J,  Valdes  Olmos  RA,  and  Voute  PA. 
131I-MIBG  as  a  first-line  treatment  in  high-risk  neuroblastoma 
patients. Nucl Med Commun. 1994; 15(9): 712-7. 
6.  Mukherjee JJ, Kaltsas GA, Islam N, Plowman PN, Foley R, Hikmat J, 
Britton  KE,  Jenkins  PJ,  Chew  SL,  Monson  JP,  Besser  GM,  and 
Grossman  AB.  Treatment  of  metastatic  carcinoid  tumours, 
phaeochromocytoma, paraganglioma and medullary carcinoma of 
the  thyroid  with  (131)I-meta-iodobenzylguanidine  [(131)I-mIBG]. 
Clin Endocrinol (Oxf). 2001; 55(1): 47-60. 
7.  Luster M, Clarke SE, Dietlein M, Lassmann M, Lind P, Oyen WJ, 
Tennvall J, and Bombardieri E. Guidelines for radioiodine therapy 
of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2008; 
35(10): 1941-59. 
8.  Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, 
Shank B, Solin LJ, and Wesson M. Tolerance of normal tissue to 
therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991; 21(1): 
109-22. 
9.  Muratet JP, Daver A, Minier JF, and Larra F. Influence of scanning 
doses of iodine-131 on subsequent first ablative treatment outcome 
in patients operated on for differentiated thyroid carcinoma. J Nucl 
Med. 1998; 39(9): 1546-50. 
10.  Norden  MM,  Larsson  F,  Tedelind  S,  Carlsson  T,  Lundh  C, 
Forssell-Aronsson  E,  and  Nilsson  M.  Down-regulation  of  the 
sodium/iodide symporter explains 131I-induced thyroid stunning. 
Cancer Res. 2007; 67(15): 7512-7. 
11.  Melis  M,  Forrer  F,  Capello  A,  Bijster  M,  Bernard  BF,  Reubi  JC, 
Krenning  EP,  and  De  Jong  M.  Up-regulation  of  somatostatin 
receptor  density  on  rat CA20948  tumors escaped  from  low  dose 
[177Lu-DOTA0,Tyr3]octreotate  therapy.  Q  J  Nucl  Med  Mol 
Imaging. 2007; 51(4): 324-33. 
12.  Sandstrom M, Garske U, Granberg D, Sundin A, and Lundqvist H. 
Individualized  dosimetry  in  patients  undergoing  therapy  with 
(177)Lu-DOTA-D-Phe (1)-Tyr (3)-octreotate. Eur J Nucl Med Mol 
Imaging. 2010; 37(2): 212-25. 
13.  Garske  U,  Sandström  M,  Johansson  S,  Sundin  A,  Granberg  D, 
Eriksson B, Lundqvist H. Minor changes in effective half-life during 
fractionated  177Lu-Octreotate  therapy.  Acta  Oncol  2012;  51(1): 
86-96. 
14.  Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, 
Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, 
Shankar  L, Dodd  L, Kaplan  R,  Lacombe  D, and  Verweij  J.  New 
response  evaluation  criteria  in  solid  tumours:  revised  RECIST 
guideline (version 1.1). Eur J Cancer. 2009; 45(2): 228-47. 
15.  Stabuc  B,  Vrhovec  L,  Stabuc-Silih  M,  and  Cizej  TE.  Improved 
prediction of decreased creatinine clearance by serum cystatin C: 
use in cancer patients before and during chemotherapy. Clin Chem. 
2000; 46(2): 193-7. 
16.  Kos J, Stabuc B, Cimerman N, and Brunner N. Serum cystatin C, a 
new  marker  of  glomerular  filtration  rate,  is  increased  during 
malignant progression. Clin Chem. 1998; 44(12): 2556-7. Theranostics 2012, 2(5) 
 
http://www.thno.org 
471 
17.  Moll S, Nickeleit V, Mueller-Brand J, Brunner FP, Maecke HR, and 
Mihatsch MJ. A new cause of renal thrombotic microangiopathy: 
yttrium  90-DOTATOC  internal  radiotherapy.  Am  J  Kidney  Dis. 
2001; 37(4): 847-51. 
18.  Valkema R, Pauwels SA, Kvols LK, Kwekkeboom DJ, Jamar F, de 
Jong M, Barone R, Walrand S, Kooij PP, Bakker WH, Lasher J, and 
Krenning EP. Long-term follow-up of renal function after peptide 
receptor  radiation  therapy  with  (90)Y-DOTA(0),Tyr(3)-octreotide 
and (177)Lu-DOTA(0), Tyr(3)-octreotate. J Nucl Med. 2005; 46 Suppl 
1: 83S-91S. 
19.  Esser JP, Krenning EP, Teunissen JJ, Kooij PP, van Gameren AL, 
Bakker  WH,  and  Kwekkeboom  DJ.  Comparison  of 
[(177)Lu-DOTA(0),Tyr(3)]octreotate  and 
[(177)Lu-DOTA(0),Tyr(3)]octreotide: which peptide is preferable for 
PRRT? Eur J Nucl Med Mol Imaging. 2006; 33(11): 1346-51. 
20.  Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS, and 
Macke  HR.  Affinity  profiles  for  human  somatostatin  receptor 
subtypes  SST1-SST5  of  somatostatin  radiotracers  selected  for 
scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000; 27(3): 
273-82. 
21.  Kwekkeboom  DJ,  Bakker  WH,  Kooij  PP,  Konijnenberg  MW, 
Srinivasan  A,  Erion  JL,  Schmidt  MA,  Bugaj  JL,  de  Jong  M,  and 
Krenning  EP.  [177Lu-DOTAOTyr3]octreotate:  comparison  with 
[111In-DTPAo]octreotide in patients. Eur J Nucl Med. 2001; 28(9): 
1319-25. 
22.  Kwekkeboom DJ, Kam BL, van Essen M, Teunissen JJ, van Eijck CH, 
Valkema  R,  de  Jong  M,  de  Herder  WW,  and  Krenning  EP. 
Somatostatin-receptor-based  imaging  and  therapy  of 
gastroenteropancreatic  neuroendocrine  tumors.  Endocr  Relat 
Cancer. 2010; 17(1): R53-73. 
23.  de Jong M, Breeman WA, Bernard BF, Bakker WH, Visser TJ, Kooij 
PP,  van  Gameren  A,  and  Krenning  EP.  Tumor  response  after 
[(90)Y-DOTA(0),Tyr(3)]octreotide  radionuclide  therapy  in  a 
transplantable rat tumor model is dependent on tumor size. J Nucl 
Med. 2001; 42(12): 1841-6. 
24.  de Jong M, Breeman WA, Bernard BF, Bakker WH, Schaar M, van 
Gameren  A,  Bugaj  JE,  Erion  J,  Schmidt  M,  Srinivasan  A,  and 
Krenning  EP.  [177Lu-DOTA(0),Tyr3]  octreotate  for  somatostatin 
receptor-targeted  radionuclide  therapy.  Int  J  Cancer.  2001;  92(5): 
628-33. 
25.  Cremonesi  M,  Ferrari  M,  Bodei  L,  Tosi  G,  and  Paganelli  G. 
Dosimetry  in  Peptide  radionuclide  receptor  therapy:  a  review.  J 
Nucl Med. 2006; 47(9): 1467-75. 
26.  Barone  R,  Borson-Chazot  F,  Valkema  R,  Walrand  S,  Chauvin  F, 
Gogou  L,  Kvols  LK,  Krenning  EP,  Jamar  F,  and  Pauwels  S. 
Patient-specific  dosimetry  in  predicting  renal  toxicity  with 
(90)Y-DOTATOC:  relevance  of  kidney  volume  and  dose  rate  in 
finding a dose-effect relationship. J Nucl Med. 2005; 46 Suppl 1: 
99S-106S. 
27.  Pauwels  S,  Barone  R,  Walrand  S,  Borson-Chazot  F,  Valkema  R, 
Kvols LK, Krenning EP, and Jamar F. Practical dosimetry of peptide 
receptor  radionuclide  therapy  with  (90)Y-labeled  somatostatin 
analogs. J Nucl Med. 2005; 46 Suppl 1: 92S-8S. 
28.  Kunikowska J, Krolicki L, Hubalewska-Dydejczyk A, Mikolajczak 
R, Sowa-Staszczak A, and Pawlak D. Clinical results of radionuclide 
therapy  of  neuroendocrine  tumours  with  90Y-DOTATATE  and 
tandem 90Y/177Lu-DOTATATE: which is a better therapy option? 
Eur J Nucl Med Mol Imaging. 2011; 38(10): 1788-97. 
29.  Brans  B,  Mottaghy  FM,  and  Kessels  A.  90Y/177Lu-DOTATATE 
therapy: survival of the fittest? Eur J Nucl Med Mol Imaging. 2011; 
38(10): 1785-7. 
30.  Oberg K, Astrup L, Eriksson B, Falkmer SE, Falkmer UG, Gustafsen 
J, Haglund C, Knigge U, Vatn MH, and Valimaki M. Guidelines for 
the  management  of  gastroenteropancreatic  neuroendocrine 
tumours  (including  bronchopulmonary  and  thymic  neoplasms). 
Part I-general overview. Acta Oncol. 2004; 43(7): 617-25. 
31.  Oberg K, Astrup L, Eriksson B, Falkmer SE, Falkmer UG, Gustafsen 
J, Haglund C, Knigge U, Vatn MH, and Valimaki M. Guidelines for 
the  management  of  gastroenteropancreatic  neuroendocrine 
tumours  (including  bronchopulmonary  and  thymic  neoplasms). 
Part II-specific NE tumour types. Acta Oncol. 2004; 43(7): 626-36. 
32.  Mitry E, Baudin E, Ducreux M, Sabourin JC, Rufie P, Aparicio T, 
Lasser P, Elias D, Duvillard P, Schlumberger M, and Rougier P. 
Treatment of poorly differentiated neuroendocrine tumours with 
etoposide and cisplatin. Br J Cancer. 1999; 81(8): 1351-5. 
33.  Ezziddin S, Opitz M, Attassi M, Biermann K, Sabet A, Guhlke S, 
Brockmann  H,  Willinek  W,  Wardelmann  E,  Biersack  HJ,  and 
Ahmadzadehfar  H.  Impact  of  the  Ki-67  proliferation  index  on 
response to peptide receptor radionuclide therapy. Eur J Nucl Med 
Mol Imaging. 2011; 38(3): 459-66. 